Hormone Therapy for Breast Cancer in Men

Hormone therapy (sometimes called endocrine therapy) is a way to treat cancer by using hormones or drugs or other treatments that affect hormones. Hormone therapy is a form of systemic therapy, like chemotherapy. It can be used after surgery (adjuvant therapy) to help lower the risk of cancer coming back, or before surgery (neoadjuvant treatment). It is also used to treat cancer that has spread, or cancer that has come back after treatment (recurred).

Some breast cancers grow in response to the hormones estrogen or progesterone. Estrogen and progesterone are usually thought of as female hormones, but men have them in their bodies also, just at lower levels. About 9 of 10 breast cancers in men are hormone receptor-positive. This makes them more likely to respond to hormone treatments. Breast cancers can be estrogen receptor (ER)-positive, or progesterone receptor (PR)-positive, or both. Hormone therapy does not help people whose tumors are both ER- and PR-negative.

What types of drugs are used in hormone therapy?

Several approaches to blocking the effects of estrogen or lowering estrogen levels are used to treat breast cancer in women. Although many of these may work in men as well, they often haven’t been studied well, if at all.

Tamoxifen and toremifene (Fareston®)

These drugs block estrogen receptors on breast cancer cells. By blocking these estrogen receptors, these drugs stop estrogen from joining to the cancer cells, and the cells stop growing. Both drugs are taken daily as a pill.

Tamoxifen is the best studied hormone drug for breast cancer in men and is most often used first. If tamoxifen doesn’t work (or stops working), other hormone drugs may be tried, but this is largely based on how well they work in women with breast cancer. Large studies of women with hormone receptor-positive cancers removed completely with surgery show that taking tamoxifen after surgery for 5 years reduces the chances of the cancer coming back by about half. Taking it for 10 years may help even more. Studies in men with breast cancer have been smaller, but indicate that taking tamoxifen after surgery for early-stage breast cancer can lower the chance of the cancer coming back and improve survival. Tamoxifen can also be used to treat metastatic breast cancer.

Toremifene works like tamoxifen, but is not used as often and is only approved for patients with metastatic breast cancer. It is not likely to work if tamoxifen has already been used and has stopped working.

The most common side effects of tamoxifen and toremifene are:

  • Hot flashes
  • Sexual problems
  • Fatigue

Some men with cancer spread to the bones may have a tumor flare with pain and swelling in the muscles and bones. This usually decreases quickly, but in some rare cases a man may also develop a high calcium level in the blood that is hard to control. If this happens, the treatment may need to be stopped for a time.

Rare, but more serious side effects are also possible:

  • Blood clots are another uncommon, but serious side effect. They usually form in the legs (called deep vein thrombosis or DVT), but sometimes a piece of clot may break off and end up blocking an artery in the lungs (pulmonary embolism or PE). Call your doctor or nurse right away if you develop pain, redness, or swelling in your lower leg (calf), shortness of breath, or chest pain, because these can be symptoms of a DVT or PE.
  • Rarely, tamoxifen has been associated with strokes in post-menopausal women. The risk in men is not clear. Tell your doctor if you have a sudden severe headache, confusion, or trouble speaking or moving.

Tamoxifen may also increase the risk of heart attacks in some patients, however this link is not clear.

Aromatase inhibitors

This group of drugs includes anastrozole (Arimidex®), letrozole (Femara®), and exemestane (Aromasin®). These drugs stop estrogen production by blocking an enzyme (aromatase) in fat tissue that converts male hormones from the adrenal glands into estrogen. Aromatase inhibitors are taken daily as pills. They have been very effective in treating breast cancer in women, but they have not been well-studied in men. Still, some doctors use them to treat advanced breast cancer in men, often combined with a luteinizing hormone-releasing hormone (LHRH) analog to turn off hormone production by the testicles (these drugs are discussed later on). These drugs are generally used if tamoxifen stops working. The main side effects are thinning of the bones and pain in muscles and joints.

Fulvestrant (Faslodex®)

Fulvestrant is a drug that also acts on estrogen receptors, but instead of blocking the receptors, this drug destroys them. Fulvestrant is used to treat metastatic breast cancer, most often after other hormone drugs (like tamoxifen and often an aromatase inhibitor) have stopped working. It is given by injection into the buttocks every 2 weeks for a month, then monthly. The most common side effects are hot flashes, mild nausea, headache, and pain at the injection site.

Luteinizing hormone-releasing hormone (LHRH) analogs and anti-androgens

In men, LHRH analogs such as leuprolide (Lupron®) and goserelin (Zoladex®) affect the pituitary gland, which regulates testosterone production in the testicles. These drugs cause the pituitary gland to turn off production of the male hormone testosterone by the testicles, leading to lower testosterone levels. They are given as shots either monthly or every few months. These drugs may be used by themselves, or combined with aromatase inhibitors or anti-androgens to treat advanced breast cancer in men.

Anti-androgens such as flutamide and bicalutamide work by blocking the effect of male hormones on breast cancer cells. These drugs are taken daily as pills.

Megestrol

Megestrol (Megace®) is a progesterone-like drug. It is unclear how it stops cancer cells from growing, but it appears to compete for hormone receptor sites in the cells. This is an older drug that is usually reserved for men who are no longer responding to other forms of hormone therapy. Megestrol may increase the risk for blood clots and frequently causes weight gain by increasing appetite.

Orchiectomy (castration)

Surgical removal of the testicles (orchiectomy) is another way to regulate hormones that might affect breast cancer growth. Removing the testicles greatly lowers the levels of testosterone and other androgens (male hormones). Most male breast cancers have androgen receptors that may cause the cells to grow. Androgens can also be converted into estrogens in the body. Orchiectomy shrinks most male breast cancers, and may help make other treatments like tamoxifen more likely to work. This was once acommon treatment for breast cancer in men, but it is now used less often because of new non-surgical approaches to lowering androgen levels, such as the LHRH analogs.

Possible side effects of hormone therapy

Although some of these drugs have unique side effects (see descriptions above), in general they can cause loss of sexual desire, trouble having an erection, weight gain, hot flashes, and mood swings. Be sure to discuss any such side effects with your cancer care team because there may be ways to treat them. See Managing Cancer-related Side Effects for more information.

The American Cancer Society medical and editorial content team
Our team is made up of doctors and master's-prepared nurses with deep knowledge of cancer care as well as journalists, editors, and translators with extensive experience in medical writing.

Cardoso F, et al. Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Annals of Oncology 0: 1–13, 2017.

Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381:805-816. Erratum in: Lancet. 2013 Mar 9;381(9869):804.

Dimitrov NV, Colucci P, Nagpal S. Some aspects of the endocrine profile and management of hormone-dependent male breast cancer. Oncologist. 2007;12-798–807.

Di Lauro L, Vici P, Del Medico P, Laudadio L, Tomao S, Giannarelli D, Pizzuti L, Sergi D, Barba M, Maugeri-Saccà M. Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer. Breast Cancer Res Treat. 2013 Aug;141(1):119-23. Epub 2013 Aug 28.

Giordano SH. A review of the diagnosis and management of male breast cancer. Oncologist. 2005;10: 471–479.

Giordano SH, Perkins GH, Broglio K, Garcia SG, Middleton LP, Buzdar AU, Hortobagyi GN. Adjuvant systemic therapy for male breast carcinoma. Cancer. 2005 Dec 1;104(11):2359-64.

Gray RG, Rea D, Handley K, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol (Meeting Abstracts) June 2013 vol. 31 no. 18_suppl 5.

Jain S and Gradishar WJ. Chapter 61: Male Breast Cancer. In: Harris JR, Lippman ME, Morrow M, Osborne CK, eds. Diseases of the Breast. 5th ed. Philadelphia, Pa: Lippincott-Williams & Wilkins; 2014.

Losurdo A et al. Controversies in clinicopathological characteristics and treatment strategies of male breast cancer: A review of the literature. Critical Reviews in Oncology/Hematology 113 (2017) 283–291.

PDQ Adult Treatment Editorial Board. Male Breast Cancer Treatment (PDQ®): Health Professional Version. 2017 Dec 15. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. Available from: https://www-ncbi-nlm-nih-gov.ezproxyhost.library.tmc.edu/books/NBK65792/. Accessed Jan 10, 2018.

Stearns V and Davidson NE. Chapter 45: Adjuvant Chemo Endocrine Therapy. In:  Harris JR, Lippman ME, Morrow M, Osborne CK, eds. Diseases of the Breast. 5th ed. Philadelphia: Wolters Kluwer Health; 2014.

Zagouri F, Sergentanis TN, Chrysikos D, Zografos E, Rudas M, Steger G, Zografos G, Bartsch R. Fulvestrant and male breast cancer: a case series. Ann Oncol. 2013 Jan;24(1):265-6.

Zagouri F, Sergentanis TN, Koutoulidis V, Sparber C, Steger GG, Dubsky P, Zografos GC, Psaltopoulou T, Gnant M, Dimopoulos MA, Bartsch R. Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series. Br J Cancer. 2013 Jun 11;108(11):2259-63. Epub 2013 May 30.

Last Medical Review: April 27, 2018 Last Revised: April 27, 2018

American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.